SEC Form 4 · accession 0001630998-16-000008
Syneos Health, Inc. · SYNH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Gibertini
Officer — President Clinical Development
Period of report
Feb 1, 2016
Accepted (ET)
Feb 2, 2016 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610950
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Feb 1, 2016 | M | 9,000 | $8.45 | A | 56,282 | D | |
| Class A Common StockF2 | Feb 1, 2016 | S | 8,000 | $40.449 | D | 48,282 | D | |
| Class A Common Stock | Feb 1, 2016 | S | 1,000 | $41.56 | D | 47,282 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)F3 | $8.45 | Feb 1, 2016 | M | 9,000 | D | — | Sep 28, 2020 | Class A Common Stock | 9,000 | 223,644 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b-1 trading plan adopted by the reporting person on September 9, 2015.
- F2The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.07 to $40.74, inclusive. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3One half of the shares subject to this option vest yearly in five equal installments beginning on September 28, 2011, subject to continued employment. The other half of the shares subject to this option vest yearly in five equal installments beginning on December 31, 2013, subject to continued employment.